Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation

Liver Transplantation

Volumn 12, Issue 1, 2006, Pages 51-57

  Firpi, Roberto J ^a   Zhu, Haizhen ^b   Morelli, Giuseppe ^a   Abdelmalek, Manal F ^a   Soldevila Pico, Consuelo ^a   Machicao, Victor I ^a   Cabrera, Roniel ^a   Reed, Alan I ^b   Liu, Chen ^b   Nelson, David R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYCLOSPORIN A; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; TSUKUBAENOLIDE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPLICON; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; CYCLOSPORINE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 33645106470     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20532     Document Type: Article

References (27)

1. Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1996: 15-29.
2. Boker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25: 203-210.
3. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29: 1220-1226.
4. Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-27S.
5. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-1143.
6. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
7. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997;64:422-426.
8. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
9. Rosen HR, O'Reilly PM, Shackleton CR, McDiarmid S, Holt C, Busuttil RW, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996;62:1773-1776.
10. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-1182.
11. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992;89:1361-1365.
12. Roayaie S, Schiano TD, Thung SN, Emre SH, Fishbein TM, Miller CM, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003;38:1428-1436.
13. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2004; 32:673-684.
14. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
15. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7: 1064-1070.
16. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004;10:1258-1262.
17. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
18. Wainberg MA, Dascal A, Blain N, Fitz-Gibbon L, Boulerice F, Numazaki K, et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 1988;72:1904-1910.
19. Vahlne A, Larsson PA, Horal P, Ahlmen J, Svennerholm B, Gronowitz JS, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol 1992;122: 61-75.
20. Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol 1994;134:303-319.
21. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
22. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
23. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol 2003;36:352-355.
24. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-S27.
25. Ghobrial RM, Colquhoun S, Rosen H, Hollis P, Ponthieux S, Pakrasi A, et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. Transplant Proc 1998;30:1470-1471.
26. Teixeira R, Papatheodoridis GV, Burroughs AK. Management of recurrent hepatitisC after liver transplantation. J Viral Hepat 2001;8:159-168.
27. Kakumu S, Takayanagi M, Iwata K, Okumura A, Aiyama T, Ishikawa T, et al. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol. 1997;12(1):62-66.